[Ways of overcoming drug resistance in patients with pulmonary tuberculosis].
To elucidate the combined effect of surfactants and antituberculous drugs, the surfactant myrastimine was tested. Two series of sputum cultures with multidrug-resistant Mycobacterium tuberculosis (MBT) strains were made. The experimental results confirmed that myramistine noticeably enhanced the sensitivity of multidrug-resistant MBT strains to antituberculous agents. The use of endobronchial and intracavernous myramistine in combination with antituberculous agents to patients with destructive pulmonary tuberculosis caused by multidrug-resistant MBT strains reduced the latter's resistance to antibiotics, cured tubendobronchitis in most patients, created conditions for obliteration of the cavernous cavity. Positive changes are noted in the first 4 months after the initiation of therapy, which can prepare patients for surgical treatment more rapidly.
Grishin
M N
MN
Svistov
V V
VV
Krivoshein
Iu S
IuS
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D012426:Russia / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology
D000995:Antitubercular Agents
Puti preodoleniia lekarstvennoĭ rezistentnosti u bol'nykh tuberkulezom legkikh.